The Expert Circle

Time to Complete

0.50 hr(s)

Release Date

January 15, 2021

Expires On

January 15, 2022

Faculty

Marc Bonaca, MD, MPH

Executive Director, CPC

Professor of Medicine, Cardiology & Vascular Medicine

Director of Vascular Research, University of Colorado SOM

Aurora, CO
Elaine Hylek, MD, MPH

Professor of Medicine

Boston University Medical Center

Boston, MA
Christian T. Ruff, MD, MPH

Assistant Professor of Medicine

Harvard Medical School

Investigator, TIMI Study Group

Cardiovascular Division

Brigham and Women’s Hospital

Boston, MA

Program Description

Unprotected, your patients with CAD and PAD are on the edge, in “limb-o” – how do we get them to become more in balance? In this activity, expert multidisciplinary faculty cover the latest guideline recommendations and clinical trial data related to managing patients with PAD post-revascularization. A patient case is woven throughout this discussion to increase opportunities for clinicians to apply knowledge to their practice.

Intended Audience

This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, hematologists and primary care physicians.

Activity Purpose

The purpose of this activity is to provide learners with an engaging, practical presentation to help them optimize anticoagulant therapy in their patients with PAD post-revascularization. Learners post-activity will also be better able to discuss limitations of various guideline recommendations for patients with PAD post-revascularization in the context of recent evidence as well as interpret the latest data on DOACs as mono- or combination therapy to develop treatment plans for these patients.

Learning Objectives

Upon completion of this activity, participants will be able to:
Optimize anticoagulant therapy prophylactically and therapeutically across diverse and complex patient populations
Discuss limitations of various guideline recommendations for prophylactic and therapeutic anticoagulation in the context of recent evidence
Interpret the latest data on DOACs as mono- or combination therapy to develop strategies for treating and protecting against thrombotic event

Method of Participation

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity, use the certificate code to log into www.achlcme.org, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

The following financial relationships have been provided:

Marc Bonaca, MD, MPH

Consultant: Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, NovoNordisk, Pfizer

Grants (through CPC, an Academic Research Organization): Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, NovoNordisk, Pfizer

Elaine Hylek, MD, MPH

Consultant: Pfizer

Research: Abbott, Bristol-Myers Squibb, Janssen

Christian Ruff, MD, MPH

Grants/Research Support (through institution): Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo

Honoraria: Anthos, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Pfizer, Portola

Grants/Research Support (through TIMI Study Group): Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Daiichi-Sankyo, Eisai, Intarcia, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, The Medicines Company, Zora Biosciences

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL).

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

0.50 hr(s)

Release Date

January 29, 2021

Expires On

January 29, 2022

Faculty

Marc Bonaca, MD, MPH

Executive Director, CPC

Professor of Medicine, Cardiology & Vascular Medicine

Director of Vascular Research

University of Colorado SOM

Aurora, CO
Matthew Menard, MD

Associate Professor of Surgery

Harvard Medical School

Co-Director of Endovascular Surgery

Brigham and Women’s Hospital

Boston, MA

Program Description

For your patients with PAD post-revascularization, what can you do to ensure the next “steps in the right direction”? In this activity, expert faculty cover the latest guideline recommendations and clinical trial data related to managing patients with PAD post-revascularization. Roundtable discussion is included to provide practical insight for clinicians to apply knowledge to their practice.

Intended Audience

This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, hematologists and primary care physicians.

Activity Purpose

The purpose of this activity is to provide learners with an engaging, practical presentation to help them optimize anticoagulant therapy in their patients with PAD post-revascularization. Learners post-activity will be better able to discuss limitations of various guideline recommendations for patients with PAD post-revascularization in the context of recent evidence as well as interpret the latest data on DOACs to develop treatment plans for these patients.

Learning Objective

Upon completion of this activity, participants will be able to:
Optimize anticoagulant therapy for patients with PAD post-revascularization
Discuss limitations of current guideline recommendations for PAD post-revascularization in the context of recent evidence
Interpret the latest data on DOACs in PAD post-revascularization

Method of Participation

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

The following financial relationships have been provided:

Marc Bonaca, MD, MPH

Consultant: Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, NovoNordisk, Pfizer

Grants (through CPC, an Academic Research Organization): Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, NovoNordisk, Pfizer

Matthew Menard, MD

Advisory Board: Janssen

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL).

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

0.50 hr(s)

Release Date

February 26, 2021

Expires On

February 26, 2022

Faculty

Gregory Piazza, MD, MS

Associate Professor of Medicine

Harvard Medical School

Staff Cardiologist, Cardiovascular Division

Brigham and Women’s Hospital

Boston, MA
Christian T. Ruff, MD, MPH

Assistant Professor of Medicine

Harvard Medical School

Investigator, TIMI Study Group

Cardiovascular Division

Brigham and Women’s Hospital

Boston, MA

Program Description

What is the latest evidence for VTE prophylaxis and treatment in obese patients and how is this different from the current guidelines? In this activity, expert cardiology faculty cover the most recent data and guideline limitations on VTE prevention and management. Roundtable discussion is included to provide practical insight to help clinicians apply knowledge to their practice.

Intended Audience

This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, hematologists and primary care physicians.

Activity Purpose

The purpose of this activity is to provide learners with an engaging, practical presentation to help them optimize anticoagulant therapy in their obese patients. Learners post-activity will also be better able to discuss limitations of various VTE guideline recommendations for obese patients in the context of recent evidence as well as interpret the latest data on DOACs as to develop VTE prophylaxis and treatment plans for these patients.

Learning Objective

Upon completion of this activity, participants will be able to:
Optimize anticoagulant therapy prophylactically and therapeutically in obese patients
Discuss limitations of various guideline recommendations for prophylactic and therapeutic anticoagulation in obese patients in the context of recent evidence
Interpret the latest data on DOACs for treating and protecting against thrombotic events in obese patients

Method of Participation

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

The following financial relationships have been provided:

Gregory Piazza, MD, MS

Consulting: Agile, Amgen, Boston Scientific Corporation, Pfizer

Grants: Bayer, Bristol Myers Squibb, Boston Scientific Corporation, Janssen, Portola

Christian Ruff, MD, MPH

Grants/Research Support (through institution): Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo

Honoraria: Anthos, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Pfizer, Portola

Grants/Research Support (through TIMI Study Group): Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Daiichi-Sankyo, Eisai, Intarcia, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, The Medicines Company, Zora Biosciences

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL).

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

0.75 hr(s)

Release Date

March 31, 2021

Expires On

March 31, 2022

Faculty

Marc Bonaca, MD, MPH

Executive Director, CPC

Professor of Medicine, Cardiology & Vascular Medicine

Director of Vascular Research, University of Colorado SOM

Aurora, CO
Alex Spyropoulos, MD

Professor of Medicine, Zucker School of Medicine

Hempstead, NY

System Director – Anticoagulation and Clinical Thrombosis, Northwell / Feinstein Institutes for Medical Research

Manhasset, NY

Program Description

What is the latest evidence for VTE prophylaxis in acutely ill medical patients and how is this different from the current guidelines? In this activity, expert cardiology faculty cover the most recent data and guideline limitations on VTE prevention in this key patient group. Roundtable discussion is included to provide practical insight to help clinicians apply knowledge to their practice.

Intended Audience

This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, hematologists and primary care physicians.

Activity Purpose

The purpose of this activity is to provide learners with an engaging, practical presentation to help them optimize anticoagulant therapy in their acutely ill medical patients. Learners post-activity will also be better able to discuss limitations of various VTE guideline recommendations for acutely ill medical patients in the context of recent evidence as well as interpret the latest data on DOACs as to develop VTE prophylaxis plans for these patients.

Learning Objective

Upon completion of this activity, participants will be able to:
Optimize anticoagulant therapy for acutely ill medical patients
Discuss limitations of current VTE prophylaxis guideline recommendations for acutely ill medical patients in the context of recent evidence
Interpret the latest data on DOACs for VTE prophylaxis in acutely ill medical patients

Method of Participation

This activity will take approximately 45 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

The following financial relationships have been provided:

Marc Bonaca, MD, MPH

Consultant: Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, NovoNordisk, Pfizer Grants (through CPC, an Academic Research Organization): Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, NovoNordisk, Pfizer

Alex Spyropoulos, MD

Consultant: Boehringer Ingelheim, Bristol-Myers Squibb, Bryer, Janssen, Portola Research Support: Boehringer Ingelheim, Janssen

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL).

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

0.50 hr(s)

Release Date

December 29, 2020

Expires On

December 29, 2021

Faculty

Marc Bonaca, MD, MPH

Executive Director, CPC

Professor of Medicine, Cardiology & Vascular Medicine

Director of Vascular Research

University of Colorado SOM

Aurora, CO
Alan M. Dietzek, MD, RPVI

Clinical Professor of Surgery

University of Vermont College of Medicine

Network Chief, Vascular and Endovascular Surgery

Linda and Stephen R. Cohen Chair in Vascular Surgery

Western Connecticut Health Network

Danbury, CT

Program Description

In this activity, expert faculty give their multidisciplinary perspectives in vascular surgery and cardiology regarding recommendations for patients with peripheral artery disease (PAD) post-revascularization. These patients are at risk for further complications and may be eligible for additional therapy. Dr. Marc Bonaca and Dr. Alan Dietzek relay practice implications of the latest guidelines and data across the various agents and combinations for patients with PAD.

Intended Audience

This activity is intended for vascular surgeons, interventional cardiologists, clinical cardiologists, and other healthcare providers who care for patients with peripheral vascular disease.

Activity Purpose

Because US peripheral artery disease (PAD) guidelines have not yet been updated, clinicians may not yet be familiar with the groundbreaking VOYAGER PAD study just published in May 2020 which showed that the addition of rivaroxaban to aspirin reduced risk of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes. It is critical for vascular surgeons, interventional cardiologists, and other healthcare providers who care for patients with PAD to understand the latest data to ensure that their patients receive the best possible care and mitigate further complications.

Learning Objective

Upon completion of this activity, participants will be able to:
Optimize anticoagulant therapy in patients with PAD post-revascularization
Discuss limitations of various guideline recommendations for patients with PAD post-revascularization in the context of recent evidence
Interpret the latest data on DOACs as mono- or combination therapy to develop strategies for patients with PAD post-revascularization

Method of Participation

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

The following financial relationships have been provided:

Marc Bonaca, MD, MPH

Consultant: Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, NovoNordisk, Pfizer

Grants (through CPC, an Academic Research Organization): Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, NovoNordisk, Pfizer

Alan M. Dietzek, MD, RPVI

No relationships to disclose

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL).

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

0.25 hr(s)

Release Date

June 18, 2021

Expires On

June 18, 2022

Faculty

Christian Ruff, MD, MPH

Director, General Cardiology, Cardiovascular Division

Brigham and Women's Hospital

Associate Professor

Harvard Medical School

Boston, MA

Program Description

Many atherosclerotic cardiovascular disease (ASCVD) patients do well after suffering a heart attack or stroke, but frequently, these patients continue to be at high risk for recurrent cardiovascular events and are not necessarily stable. It is important to understand the patients, particularly those with polyvascular disease, at higher risk for recurrent events. Are you current with how to best manage these patients? Find out in this short vlog, where Dr. Christian Ruff from Brigham and Women's and Harvard Medical School, discusses the COMPASS trial and its implications for patients with stably unstable polyvascular disease.

Intended Audience

This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, and primary care physicians

Activity Purpose

The purpose of this activity is to provide learners with an engaging, concise presentation to help them optimize anticoagulant therapy in their patients with polyvascular disease. Learners post-activity will also be better able to interpret the latest data on DOACs as for patients with stably unstable ASCVD.

Learning Objective

Upon completion of this activity, participants will be able to:
Identify stably unstable patients with chronic ASCVD that are at increased risk for recurrent events and complications
Outline the potential risks and complications of patients with polyvascular disease in comparison with those patients with only CAD
Compare and contrast treatment strategies for patients with CAD and PAD

Method of Participation

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Christian Ruff, MD, MPH

Consultant (Occasional): Anthos, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Portola

Grant/Research Support recipient: Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL).

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

1.00 hr(s)

Release Date

July 09, 2021

Expires On

July 09, 2022

Chair

Alex Spyropoulos, MD, FACP, FCCP, FRCPC

Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell

Professor, Feinstein Institutes for Medical Research

System Director, Anticoagulation and Clinical Thrombosis Northwell Health

Hempstead, NY

Faculty

Mark Goldin, MD

Associate Professor of Medicine

Zucker School of Medicine at Hofstra/Northwell

Hempstead, NY
Gregory Piazza, MD, MS

Director, Vascular Medicine Section, Division of Cardiovascular Medicine

Brigham and Women's Hospital

Boston, MA

Program Description

Why should hospitalists, cardiologists, and other clinicians care about optimal post-discharge prophylaxis in patients with acute medical illness? What strategies are available to better ensure optimal post-discharge prophylaxis in this patient population? This clinical commentary features leading thrombosis expert, Dr. Alex Spyropoulos, and a multidisciplinary panel, covering these important questions and how clinicians can ensure that they optimally incorporate these recommendations into their health system.

Intended Audience

This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, hospitalists and primary care physicians.

Activity Purpose

The purpose of this activity is to provide learners with an engaging, practical presentation to help them optimize post-discharge prophylaxis in their acutely ill medical patients. Faculty highlight the latest strategies (e.g. tools, EHR systems) to facilitate optimal post-discharge prophylaxis in this patient population. Learners post-activity will be better able to discuss limitations of various VTE prophylaxis guideline recommendations for these patients in the context of recent evidence as well as interpret the latest data on DOACs as to develop VTE prophylaxis plans for these patients.

Learning Objective

Upon completion of this activity, participants will be able to:
Optimize anticoagulant therapy for patients with acute medical illness post-discharge
Discuss limitations of various VTE prophylaxis guideline recommendations for patients with acute medical illness in the context of recent evidence
Interpret the latest data on DOACs to develop strategies optimizing post-discharge VTE prophylaxis in patients with acute medical illness
Identify patients that would benefit from DOAC therapy post-discharge

Method of Participation

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Mark Goldin, MD

Grant/Research Support: Janssen

Gregory Piazza, MD, MS

Grant/Research Support: Amgen, Bayer, BMS/Pfizer Alliance, Boston Scientific Corporation, Janssen, Portola

Alex Spyropoulos, MD, FACP, FCCP, FRCPC

Consultant: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Portola, Sanofi Grant/Research Support: Boehringer Ingelheim, Janssen

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Rivaroxaban for patients with PAD post-revascularization

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

This activity is sponsored by the Academy for Continued Healthcare Learning.

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

0.50 hr(s)

Release Date

July 30, 2021

Expires On

July 30, 2022

Faculty

Marc Bonaca, MD, MPH

Executive Director, CPC

Professor of Medicine, Cardiology & Vascular Medicine

Director of Vascular Research, University of Colorado SOM

Aurora, CO

Program Description

Are your patients with PAD post-revascularization “on a limb”? Find out as Marc Bonaca, MD, MPH covers the latest guideline recommendations and clinical trial data related to managing patients with PAD post-revascularization. This expert perspective provides clinicians with practical insights to apply to their practice.

Intended Audience

This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, and primary care physicians.

Activity Purpose

The purpose of this activity is to provide learners with an engaging, practical presentation to help them optimize anticoagulant therapy in their patients with PAD post-revascularization. Learners post-activity will be better able to interpret the latest data on DOACs in PAD post-revascularization as well as optimize anticoagulant therapy for these patients.

Learning Objective

Upon completion of this activity, participants will be able to:
Interpret the latest data on DOACs in PAD post-revascularization
Optimize anticoagulant therapy for patients with PAD post-revascularization

Method of Participation

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Marc Bonaca, MD, MPH

Consultant (through CPC, an Academic Research Organization): Amgen, AstraZeneca, Audentes, Bayer, Cook, Janssen, Lexicon, Merck, NovoNordisk, PhaseBio, Regeneron, Sanifit, Wraser

Grants (through CPC, an Academic Research Organization): Amgen, ARCA BioPharma, AstraZeneca, Bayer, Janssen, Lexicon, NovoNordisk

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Rivaroxaban for patients with PAD post-revascularization

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

0.25 hr(s)

Release Date

Aug 27, 2021

Expires On

Aug 27, 2022

Faculty

Mark Goldin, MD

Associate Professor of Medicine

Zucker School of Medicine at Hofstra/Northwell

Hempstead, NY

Program Description

Did you know that hospitalized acutely ill medical patients remain at risk for venous thromboembolism (VTE) well past the time of discharge? In this short vlog, learn how to identify risk factors and avoid this complication as Dr. Mark Goldin shares a hospitalist’s perspective on the latest updates on postdischarge VTE prophylaxis for acutely ill medical patients. Dr. Goldin also discusses innovative interdisciplinary tools to promote appropriate postdischarge for these patients.

Intended Audience

This activity is intended for clinical cardiologists, interventional cardiologists, hospitalists and primary care physicians.

Activity Purpose

The purpose of this activity is to provide learners with an engaging, accessible vlog activity to help them optimize postdischarge prophylaxis in their acutely ill medical patients. Expert faculty highlight the latest strategies (e.g. tools, EHR systems) to facilitate optimal postdischarge prophylaxis in this patient population. Learners’ post-activity will be better able to understand the importance of postdischarge prophylaxis in this patient population as well as interpret the latest data on DOACs as to develop VTE prophylaxis plans for these patients.

Learning Objective

Upon completion of this activity, participants will be able to:
Recognize the importance of optimal postdischarge prophylaxis for acutely ill medical patients
Evaluate the latest safety and efficacy data for postdischarge prophylaxis in the acutely ill medical population
Evaluate potential tools and strategies to facilitate proper postdischarge prophylaxis for acutely ill medical patients

Method of Participation

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Mark Goldin, MDMark Goldin, MD

Grant/Research Support: Janssen

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

0.25 hr(s)

Release Date

Sep 30, 2021

Expires On

Sep 30, 2022

Faculty

Gregory Piazza, MD, MS

Director, Vascular Medicine Section, Division of Cardiovascular Medicine

Brigham and Women's Hospital

Boston, MA

Program Description

As the COVID-19 pandemic continues to wage on, are you prepared to prevent and treat your patients for COVID-19-related venous thromboembolism (VTE)? In this short vlog, learn how to develop appropriate regimens with antithrombotic therapy for this patient population and hear about the promising PREVENT-HD trial. Leading VTE expert, Dr. Gregory Piazza, outlines key real-world insights that you need to know about these patients and their risk for VTE.

Intended Audience

This activity is intended for clinical cardiologists, hospitalists, interventional cardiologists, internal medicine, primary care physicians, and vascular surgeons.

Activity Purpose

The purpose of this activity is to provide learners with an engaging, accessible vlog activity to help them better understand the pathophysiology with COVID-19 and thromboembolism, the latest recommendations for antithrombotic therapy in patients with COVID-19, and the most recent information on promising trials with COVID-19 and VTE prevention. Learners post-activity will be better able to ensure that this patient population receives optimal VTE prophylaxis to guarantee the best possible outcomes.

Learning Objective

Upon completion of this activity, participants will be able to:
Develop appropriate regimens with antithrombotic therapy for patients with COVID-19
Outline key characteristics of the PREVENT-HD trial

Method of Participation

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Gregory Piazza, MD, MS

Grant/Research Support: Amgen, Bayer, BMS/Pfizer Alliance, Boston Scientific Corporation, Janssen, Portola

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Rivaroxaban for non-hospitalized patients with COVID-19; fondaparinux as VTE prevention in noncritically ill patients with COVID-19; postdischarge VTE prophylaxis with LMWH in hospitalized patients with COVID-19

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

0.25 hr(s)

Release Date

November 9, 2021

Expires On

November 9, 2022

Faculty

Anahita Dua, MBChB, MBA, MSc

Vascular Surgeon

Director MGH Vascular Lab

Co-Director of the MGH Vascular Lab

Associate Director of the MGH Wound Care Center

Massachusetts General Hospital

Boston, MA

Program Description

This vlog provides learners with the perspective of a leading vascular medicine expert, Dr. Anahita Dua, on recent advances and practical considerations for patients with PAD post-revascularization. Talking points include the latest approvals and evidence, real-world implications of these recent advances, and roles of the interdisciplinary team in the management of this patient population.

Intended Audience

This activity is intended for cardiologists, hospitalists, primary care clinicians, vascular surgeons, and other clinicians in the interdisciplinary PAD team.

Activity Purpose

The purpose of this activity is to provide learners with a brief and engaging activity to provide current guidance and limitations with recommendations for patients with PAD post-revascularization, as well as understand the implications of recent evidence. Learners post-activity will be better able to tailor personalized treatment regimens for patients with PAD post-revascularization with respect to the latest clinical trial data and expert insights, and understand the role of the interdisciplinary team with post-revascularization care.

Learning Objective

Upon completion of this activity, participants will be able to:
Identify current antiplatelet and anticoagulant practices for patients with PAD post-revascularization
Outline practical implications of recent advances for patients with peripheral artery disease (PAD) post-revascularization
Create effective treatment plans for patients with PAD post-revascularization secondary to the latest research and expert insights

Method of Participation

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Anahita Dua, MBChB, MBA, MSc

Speaker (Education): MiMedx Group, Inc. and Penumbra, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Aspirin for PAD, dual antiplatelet therapy (DAPT) for symptomatic PAD with recent coronary stent or acute coronary syndrome, DAPT for PAD post-endovascular revascularization

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

0.50 hr(s)

Release Date

December 17, 2021

Expires On

December 17, 2022

Faculty

Christian T. Ruff, MD, MPH

Director, General Cardiology, Cardiovascular Division

Brigham and Women's Hospital

Associate Professor of Medicine

Harvard Medical School

Boston, MA

Program Description

Hear from Christian Ruff, MD, MPH on the latest clinical trial data related to DOACs and implications for patient care. This expert perspective provides clinicians with practical insights to apply to their practice. Dr. Ruff discusses the most recent evidence with DOACs across a multitude of disease states, including acute venous thromboembolism in patients with elevated BMI, peripheral artery disease, and COVID-19. Exciting new evidence with the novel factor XIa drug class is also covered.

Intended Audience

This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, hospitalists and primary care physicians.

Activity Purpose

The purpose of this activity is to provide learners with a succinct and comprehensive review based on the latest DOAC clinical trial data. Clinicians learn about the most recent DOAC evidence in a multitude of disease states, including acute venous thromboembolism in patients with elevated BMI, peripheral artery disease, and COVID-19. Exciting new evidence with the novel factor XIa drug class is also covered.

Learning Objectives

Upon completion of this activity, participants will be able to:
Evaluate the latest clinical trial data on DOACs
Incorporate DOACs into appropriate prophylaxis and/or treatment plans based on recent evidence

Method of Participation

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Christian T. Ruff, MD, MPH

Consultant (Occasional): Anthos, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Alexion (formally Portola)

Grant/Research Support recipient: Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Use of DOACs in patients with elevated BMI, patients with COVID-19, LV thrombus, chronic kidney disease. Discussion of investigational milvexian.

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org

Time to Complete

1.00 hr(s)

Release Date

December 20, 2021

Expires On

December 20, 2022

Faculty

Marc Bonaca, MD, MPH

Executive Director, CPC

Professor of Medicine, Cardiology & Vascular Medicine

Director of Vascular Research

University of Colorado SOM

Aurora, CO
Sean Lyden, MD

Department Chair, Vascular Surgery

Cleveland Clinic

Cleveland, OH
Raghu Kolluri, MD, MS, RVT, FSVM

System Medical Director

Vascular Medicine & Vascular Laboratories

OhioHealth Heart & Vascular

Clinical Professor of Medicine

Ohio University HCOM

President, Syntropic Core Lab

Columbus, OH

Program Description

Dr. Marc Bonaca, Dr. Sean Lyden and Dr. Raghu Kolluri discuss how to properly incorporate direct oral anticoagulants (DOACs) into treatment plans for patients with peripheral artery disease (PAD). They evaluate the latest data on DOAC therapy and provide strategies for treating and protecting against thrombotic events in patients with PAD post-revascularization.

Intended Audience

This activity is intended for vascular surgeons, interventional cardiologists, clinical cardiologists, and other healthcare providers who care for patients with peripheral vascular disease.

Activity Purpose

Because US peripheral artery disease (PAD) guidelines have not yet been updated, clinicians may not yet be familiar with the groundbreaking VOYAGER PAD study just published in May 2020 which showed that the addition of rivaroxaban to aspirin reduced risk of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes. It is critical for vascular surgeons, interventional cardiologists, and other healthcare providers who care for patients with PAD to understand the latest data to ensure that their patients receive the best possible care and mitigate further complications.

Learning Objectives

Upon completion of this activity, participants will be able to:
Interpret the latest data on DOACs in PAD post-revascularization
Optimize anticoagulant therapy for patients with PAD post-revascularization
Interpret the latest data on DOACs as mono- or combination therapy to develop strategies for treating and protecting against thrombotic events

Method of Participation

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

Cleveland Clinic Center for Continued Education requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Marc Bonaca, MD, MPH

Sources of Funding for Research/Independent Contractor: Amgen, ARCA BioPharm , AstraZeneca, Janssen, Lexicon, NovoNordisk

Consulting Agreements: Amgen, AstraZeneca, Audentes Pharmaceuticals, Cook, Janssen, Lexicon, Merck, NovoNordisk, PhaseBio Pharmaceuticals, Regeneron, Sanifit, Wraser

Sean Lyden, MD

Consulting Agreements: Abbott Vascular, Boston Scientific, Centerline Biomedical, Endologix, Intact Vascular, Medtronic, Penumbra, Inc., Philips Healthcare, PQ Bypass, Inc., Shockwave Medical, Inc.

Board Membership: VIVA Physicians

Raghu Kolluri, MD, MS, RVT, FSVM

Consulting Agreements: Abbott Vascular, Boston Scientific, Inari Medical, Medtronic, Penumbra, Inc., Philips Healthcare, Surmodics, Vesper

CEC Member: Mercator Medsystem, Inc.

Steering Committee (for a clinical trial): Penumbra, Inc.

Data and Safety Monitoring Board: Thrombolex

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Accreditation and Credit Designation

In support of improving patient care, Cleveland Clinic Center for Continuing Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Cleveland Clinic Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

Sponsored by the Cleveland Clinic Center for Continuing Education.

Academy for Continued Healthcare Learning (ACHL) is the educational partner.

Supporter Information

Supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

Cleveland Clinic Center for Continuing Education and ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Karen Catino
kcatino@achlcme.org

Time to Complete

1.50 hr(s)

Release Date

April 29, 2022

Expires On

April 29, 2023

Faculty

Kush Desai, MD, FSIR

Associate Professor of Radiology, Surgery, and Medicine

Division of Interventional Radiology

Northwestern University Feinberg School of Medicine

Chicago, IL
Anahita Dua, MBChB, MBA, MSc

Vascular Surgeon

Director MGH Vascular Lab

Co-Director of the MGH Vascular Lab

Associate Director of the MGH Wound Care Center

Massachusetts General Hospital

Boston, MA
Christian T. Ruff, MD, MPH

Director, General Cardiology, Cardiovascular Division

Brigham and Women's Hospital

Associate Professor of Medicine

Harvard Medical School

Boston, MA

Program Description

In three fast-paced modules, a multispecialty panel of cardiology, radiology, and vascular surgery experts provide perspectives on preventing adverse limb events in patients undergoing revascularization. Vascular medicine expert Dr. Anahita Dua moderates these brief discussions and case presentations with a focus on the latest clinical trial data and implications for patient care.

Intended Audience

This activity is intended for vascular surgeons, interventional cardiologists, clinical cardiologists, and other HCPs who care for patients with peripheral vascular disease.

Activity Purpose

Dual antiplatelet therapy is used to reduce risks in patients with PAD who undergo lower extremity revascularization, but regimens and practices vary widely. Further, new data on the benefits of dual pathway inhibition by targeting both platelets and thrombin may change approaches for these high-risk, vulnerable patients. Expert discussion and case-based application can help clinicians apply the latest data.

Learning Objectives

Upon completion of this activity, participants will be able to:
Interpret the latest data on DOACs in PAD post-revascularization
Optimize anticoagulant therapy for patients with PAD post-revascularization secondary to patient-specific factors (e.g. type of revascularization, comorbidities, concomitant medications)

Method of Participation

This activity will take approximately 90 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Faculty Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Kush Desai, MD, FSIR

Advisor or Review Panel Member: Boston Scientific Corporation, Cardinal Health, Medtronic, Philips, Tactile Medical

Grant/Research Support Recipient: Boston Scientific Corporation

Consultant: Becton, Dickinson and Company, Boston Scientific Corporation, Cardinal Health, Cook Medical, W. L. Gore & Associates, Medtronic, Philips, Shockwave Medical, Tactile Medical

Speakers' Bureau: Becton, Dickinson and Company, Boston Scientific Corporation, Cook Medical, Medtronic, Tactile Medical

Anahita Dua, MBChB, MBA, MSc

Speaker (Education): MiMedx Group, Inc. and Penumbra, Inc.

Christian T. Ruff, MD, MPH

Consultant (Occasional): Anthos, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Alexion (formally Portola)

Grant/Research Support recipient: Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Use of anticoagulants not approved for patients with PAD.

Accreditation and Credit Designation

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for up to 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsor Information

This activity is sponsored by the Academy for Continued Healthcare Learning.

Supporter Information

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Manager

Laurie Novoryta
lnovoryta@achlcme.org